- 24 h
- letzte 200 News
| Zeit | Aktuelle Nachrichten | ||
|---|---|---|---|
| Fr | FDA approves Ionis' TRYNGOLZA for FCS treatment | ||
| Fr | FDA confirms end of Eli Lilly's tirzepatide shortage after re-evaluation | ||
| Fr | Setback for UK pharma as government sets unexpectedly high VPAG payback rate in 2025 | ||
| Fr | Palleon and Shanghai Henlius Biotech link on autoimmune therapy | ||
| Fr | Astellas and Sangamo sign capsid deal for neurological diseases | ||
| Fr | Magazine: US reproductive laws could limit women's participation in clinical trials | ||
| Do | FDA approves Mesoblast's Ryoncil for SR-aGvHD treatment | ||
| Do | MSD makes obesity play in up to $2bn deal for Hansoh's GLP-1RA asset | ||
| Do | BioAge and Novartis seek drug targets for ageing-related diseases | ||
| Do | Novo Holdings completes Catalent acquisition for $16.5bn | ||
| Mi | Pharma's data and analytics market forecast to reach to $2.1bn by 2028 | ||
| Mi | The healthcare sector must change its industrial refrigeration methods to reduce its emissions | ||
| Mi | Petrovax announces positive results from long-CoV-III-21 trial of Longidaza for long-term pulmonary sequelae of COVID-19 | ||
| Mi | Abera and Orexo partner for vaccine powder formulations | ||
| Mi | Oncology R&D: emerging therapies and new challenges? | ||
| Mi | FDA targets more online vendors selling unapproved GLP-1RA products | ||
| Mi | Gilead and Terray link to develop small-molecule therapies | ||
| Mi | Egyptian Drug Authority approves Lilly and EVA's insulin injection | ||
| Di | Novo Nordisk invests $1.2bn in new Denmark facility | ||
| Di | Biotech bounces back as venture funding grows $3.8m from 2023 to 2024YTD | ||
| Di | China NMPA approves MSD's KEYTRUDA for stages of NSCLC | ||
| Di | Bavarian Nordic signs mpox vax deal with Serum Institute of India | ||
| Di | CTO Europe 2024: keep the burden of trials away from patients, say experts | ||
| Di | ADCs breach barriers to become mainstream cancer treatment | ||
| Di | GSK's lung cancer therapy gains EMA PRIME designation |
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
